Gene Signal Novel Corneal Neovascularization Product Still On Track Despite Primary Endpoint Miss
This article was originally published in The Pink Sheet Daily
Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.
You may also be interested in...
A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.